DEF: LifeStance Health 2026 Proxy Statement Overview

LifeStance Health Group, Inc. has released its 2026 proxy statement detailing director elections, executive compensation, and the ratification of its independent auditor.

Summary

• The 2026 Annual Meeting of Stockholders is scheduled for June 2, 2026, in a fully virtual format.
• Stockholders will vote on the election of two Class II directors, the ratification of PwC as the independent auditor for 2026, and an advisory vote on executive compensation.
• The company reported 2025 total revenue of $1.42 billion, a 14% increase year-over-year.
• Adjusted EBITDA for 2025 was $157.7 million, representing a 32% increase from the prior year.
• The clinician base grew to 8,040, and visit volumes reached 9.0 million in 2025.
• The Board of Directors is reducing its size to eight members effective upon the conclusion of the Annual Meeting.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a stable, routine proxy filing that highlights solid financial growth and a successful leadership transition, though it notes the ongoing governance adjustments required by the loss of 'controlled company' status.

Positives

• Total revenue increased 14% to $1.42 billion in 2025.
• Adjusted EBITDA grew 32% to $157.7 million.
• Clinician base expanded by 9% to 8,040.
• Visit volumes increased by 14% to 9.0 million.
• The company achieved net income of $9.7 million for the full year 2025.

Negatives

• The company experienced a leadership transition in 2025, including the departure of the former Chief Digital Officer.
• The company is no longer a 'controlled company' under Nasdaq rules, necessitating a transition to fully independent board committees.
• Two directors, Darren Black and Eric Shuey, are not standing for re-election.

Risks

• The company faces risks associated with cybersecurity and the integrity of information technology systems.
• The company is subject to regulatory compliance risks and potential changes in legal requirements.
• The company's classified board structure may make it more difficult for third parties to acquire the company.
• The company's performance is dependent on its ability to attract and retain clinicians.

Future Outlook

The company's 2026 guidance reflects continued positive momentum, projecting further growth and profitability improvements based on confidence in the new leadership team.

Management Comments

• Management believes the 2025 financial performance was strong, driven by operational improvements and disciplined capital deployment.
• The Board believes the classified board structure is in the best interests of the company to ensure continuity and stability.
• The company believes hosting a virtual meeting allows for greater stockholder attendance and participation.

Industry Context

StockSavvy.ai notes that LifeStance is navigating a transition from a high-growth, sponsor-backed entity to a more mature, publicly-governed healthcare provider, aligning with broader trends in the behavioral health sector toward scale and operational efficiency.

Comparison to Industry Standards

• The company benchmarks its executive compensation against a peer group including Addus HomeCare, agilon health, Hims & Hers Health, and Teladoc Health.
• The company's use of Adjusted EBITDA as a primary performance metric is consistent with standard practices for high-growth healthcare services companies.

Management Changes

Corporate Governance

Legal Proceedings

• None mentioned.

Related Party Transactions

• The company maintains a stockholders agreement with TPG and Summit Partners regarding director nomination rights.
• The company has a registration rights agreement with certain stockholders, including Sponsor Investors.

Stakeholder Impact

• Stockholders are asked to vote on key governance and compensation matters.
• The virtual meeting format is intended to increase accessibility for all stockholders.

Next Steps

• Hold the Annual Meeting of Stockholders on June 2, 2026.
• Publish final vote counts on a Form 8-K within four business days after the meeting.
• Continue the transition to fully independent board committees as required by Nasdaq rules.

Key Dates

Recommendation

The filing is a standard annual proxy statement. While it confirms strong financial performance, it does not contain new, unexpected material information that would typically trigger a significant shift in investment thesis.

Keywords

LifeStance Health, Proxy Statement, Executive Compensation, Corporate Governance, Mental Healthcare, Annual Meeting